Ulf Andréasson

Analytical and clinical validation of the Lumipulse G plasma p‐tau217 assay for clinical implementation

Burak Arslan, Johan Gobom, Ulf Andréasson, Laia Montoliu‐Gaya et autres

INTRODUCTION: Although several plasma tau phosphorylated at threonine 217 (p-tau217) immunoassays are now available, comprehensive analytical validation remains limited. We therefore evaluated the Lumipulse G plasma p-tau217 assay and verified established cutoffs for clinical implementation. METHODS: This study was conducted in two …

se, us, ca, cn, fr, gb (code pays fourni par la source)

Fluid biomarkers for neurodegenerative diseases: a comprehensive update

Martina Valletta, Nils Briel, Idil Yuksekel, Michelle Barboure et autres

Abstract Fluid biomarkers are revolutionizing the diagnosis and management of neurodegenerative diseases by enabling earlier diagnosis and disease monitoring. In particular, blood-based biomarkers have emerged as a minimally invasive and scalable alternative to cerebrospinal fluid analysis. Recent advances in blood-based tau biomarkers …

se, ch, fr, nl, es, us, hk, gb, cn (code pays fourni par la source)

Fluid biomarkers for neurodegenerative diseases: a comprehensive update

Martina Valletta, Nils Briel, Idil Yuksekel, Michelle Barboure et autres

Abstract Fluid biomarkers are revolutionizing the diagnosis and management of neurodegenerative diseases by enabling earlier diagnosis and disease monitoring. In particular, blood-based biomarkers have emerged as a minimally invasive and scalable alternative to cerebrospinal fluid analysis. Recent advances in blood-based tau biomarkers …

se, ch, fr, nl, es, us, hk, gb, cn (code pays fourni par la source)

Additional file 1 of Fluid biomarkers for neurodegenerative diseases: a comprehensive update

Martina Valletta, Nils Briel, Idil Yuksekel, Michelle Barboure et autres

Supplementary Material 1.

se, ch, fr, nl, es, us, hk, gb, cn (code pays fourni par la source)

Additional file 1 of Fluid biomarkers for neurodegenerative diseases: a comprehensive update

Martina Valletta, Nils Briel, Idil Yuksekel, Michelle Barboure et autres

Supplementary Material 1.

se, ch, fr, nl, es, us, hk, gb, cn (code pays fourni par la source)

Fluid biomarkers for neurodegenerative diseases: a comprehensive update

Martina Valletta, Nils Briel, Idil Yuksekel, Michelle Barboure et autres

Fluid biomarkers are revolutionizing the diagnosis and management of neurodegenerative diseases by enabling earlier diagnosis and disease monitoring. In particular, blood-based biomarkers have emerged as a minimally invasive and scalable alternative to cerebrospinal fluid analysis. Recent advances in blood-based tau biomarkers have …

se, ch, fr, nl, es, us, hk, gb, cn (code pays fourni par la source)

The relationship between CSF/serum immunoglobulin and albumin ratio across laboratories: a retrospective, multi-center study

Harald Hegen, Ulf Andréasson, Juan J Archelos-Garcia, Gerhard Bachmaier et autres

BACKGROUND: The relationship between cerebrospinal fluid (CSF)/serum immunoglobulin (Ig) ratios (QIg) and CSF/serum albumin ratio (Qalb) is a commonly used biomarker in routine CSF diagnostics. It is used to quantitatively determine the presence of an intrathecal Ig synthesis, which is important for …

at, se, cn, fr, nl, ch, us, gb (code pays fourni par la source)

Influence of pneumatic tube system transport on cell count and spectrophotometry in cerebrospinal fluid

Marcus Clarin, Joel Simrén, Johanna Svanberg, Hanna Fahlén et autres

Pneumatic tube systems (PTS) are routinely used in many hospitals for transporting collected body fluid samples and to reduce turnaround time. However, their use for transport of CSF is not widespread, in part due to ambiguous or non-existing data regarding possible impact …

us, se, gb (code pays fourni par la source)

Comparative analysis of plasma p-tau217 immunoassays: challenges for standardization and harmonization

Burak Arslan, Johan Gobom, Ulf Andréasson, Fernando González‐Ortiz et autres

se, us, gb (code pays fourni par la source)

Alpha-internexin as a brain-specific neurodegeneration marker: development and validation of a novel CSF assay

Francisco J. Meda, Anna Dittrich, Ingmar Skoog, Silke Kern et autres

BACKGROUND: Alpha-internexin (AINX) is a type IV intermediate filament alongside the neurofilament triplet proteins and periferin. Despite its homologies, the key difference is that AINX is central nervous system-specific. The purpose of this study was to develop an immunoassay for cerebrospinal fluid …

se, gb, us, in (code pays fourni par la source)

Method comparison of plasma and CSF GFAP immunoassays across multiple platforms

Burak Arslan, Elzbieta Rembeza, Sofia Rasch, Ulf Andréasson et autres

OBJECTIVES: Glial fibrillary acidic protein (GFAP) is a biomarker of astrocytic activation associated with neurodegenerative diseases, neuroinflammatory disorders, and traumatic brain injury. However, the lack of standardized methods for quantifying GFAP across different immunoassay platforms poses challenges for its clinical implementation. This …

se, cn, fr, us, gb (code pays fourni par la source)

Validation of a plasma GFAP immunoassay and establishment of age-related reference values: bridging analytical performance and routine implementation

Burak Arslan, Ulf Andréasson, Elzbieta Rembeza, Markus Axelsson et autres

Abstract Objectives Glial fibrillary acidic protein (GFAP) is a well-established biomarker of astrocytic activation associated with neurodegenerative diseases, neuroinflammatory disorders, and traumatic brain injury. With increasing interest in blood-based biomarkers, the need for analytically validated assays and reliable reference intervals is critical …

se, no, cn, fr, us, gb (code pays fourni par la source)